DBV Technologies stock
DBV.PAPARDBV Technologies S.A., HealthcareISIN FR0010417345
40Score 40 out of 100, Weak
Price and trend
50 / 100
Price history
−13% in one yearThe chart shows daily closes over 15 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 25% below it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 68).
The price is 50% below its 52-week high. Largest decline in 15 years: 99% (October 2017 to November 2024).
Chart figures for advanced users
- SMA 50$2.13
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.14
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)68
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.74
- The lowest closing price of the last twelve months.
- Resistance$4.72
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- DBV Technologies S.A. belongs to the Biotechnology industry (France) and, with a market value of $738.12M, is number 209 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 40 out of 100 (Weak): rank 536 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $194.19M, financial debt $7.99M (fiscal 2025).Stability 69
Weaknesses
- DilutionShare count up 158% since 2020.Capital allocation 55
- Loss-makingLoss of $208.16M over the last 12 months.Fundamentals 20
- Negative free cash flowFree cash flow −$192.19M over the last 12 months.Fundamentals 20
The score is held back by fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 41 to 40.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. Last 12 months: net −100%. From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
Fiscal 2025Debt is low; no interest coverage is reported.
Earnings
- Next earnings
- 11 Mar 2027in 118 days
- Last reported
- 28 Oct 2026EPS reported −0.03 (expected −0.05)above expectations
Analyst estimates
- Earnings per share
- −0.23−54.7%
- Revenue
- $3.2M+22.5%
- Earnings per share
- −0.14−67.1%
- Revenue
- $65.52M−10.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −5.1%DBV Technologies confirms its timeline, still expects a Priority Review and plans the toddler BLA submission in 2027, without changing its outlook.
“We'll continue our dialogue with the FDA over the next few months and expect to submit a toddler BLA in 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
What happened at DBV Technologies
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 40
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AlumisALMS $793.44M38
- ArdelyxARDX $784.28M34
- Olema PharmaceuticalsOLMA $760.22M34
- GubraGUBRA.CO $738.91M43
- Aura BiosciencesAURA $737.34M41
- Attovia TherapeuticsATTO $722.72M44
- OmniAbOABI $722.01M54
- Prime MedicinePRME $705.56M37
ETFs that hold DBV Technologies
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.06% | 0.28% | €630.46M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.03% | 0.30% | €3.45B |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.01% | 0.34% | €16.96M |
Show 2 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.00% | 0.45% | €1.54B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.